Clinical trials: Androgenetic Alopecia (AGA), active
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
This study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of N1087 compared with placebo in adult men with androgenetic alopecia (male pattern hair loss).
- Trial name
- MINORA-MEN (NCT07529977)
- Testing
- Minoxidil oral solution
- Where
- Brazil
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
This is a first-in-human study of ABS-201, a new investigational medicine, in healthy adult men and women. Its main purpose is to find out whether ABS-201 is safe and well tolerated, as well as to understand how the body…
- Trial name
- NCT07317544
- Testing
- SAD IV Dose 1 - 150mg ABS201 IV Single Dose, ABS-201 SC Multiple Doses
- Where
- 5 sites in Australia
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Absci Pty Ltd.
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Androgenetic Alopecia (AGA), Androgenetic Alopecia
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that…
- Conditions
- Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
- Trial name
- NCT07146022
- Testing
- VDPHL01 QD, VDPHL01 BID
- Where
- 71 sites in United States
- Volunteers
- 552 people
- Sponsor
- Veradermics, Inc.
Androgenetic Alopecia (AGA)
Exosome Therapy for Male Androgenetic Alopecia
The goal of this clinical trial is to learn if local scalp injection of human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) can treat androgenetic alopecia (AGA) in male patients with AGA.
- Trial name
- NCT07693244
- Testing
- Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes, Normal Saline (0.9% NaCl)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhang Han
Androgenetic Alopecia (AGA)
Multi-Omics Insights Into Androgenetic Alopecia
This study utilizes a multi-omics approach to systematically characterize the cellular heterogeneity and spatial architecture of the hair follicle microenvironment in patients with androgenetic alopecia (AGA).
- Trial name
- NCT07603544
- Testing
- Collection of ~2 × 12 mm scalp tissue, Single-cell sequencing and spatial transcriptome sequencing
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Androgenetic Alopecia (AGA)
VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia
This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia.
- Trial name
- VENEZE-AGA (NCT07536100)
- Testing
- Veneze peptide hair serum, Topical minoxidil
- Where
- 2 sites in Thailand
- Volunteers
- 80 people
- Sponsor
- Institute of Dermatology, Thailand
Telogen Effluvium, Female Pattern Hair Loss
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth
- Conditions
- Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia, Male Pattern Baldness
- Trial name
- NCT06648850
- Testing
- DA-001, Phenylephrine, DA-001 Topical + DA-005 Oral (HIF-1α supplement)
- Volunteers
- 1,120 people
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
The Effect of Nanofat Injection on Androgenetic Alopecia
Androgenetic alopecia is a condition that bothers a lot of people. The disadvantage of the FDA approved topical minoxidil is that the patient needs to be compliant every day for extended periods of time.
- Trial name
- NCT07518342
- Testing
- Minoxidil 5 %, PRP injection, Nanofat injection
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Androgenetic Alopecia (AGA)
Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia
This is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate whether topical application of Lactobacillus reuteri can safely and effectively treat androgenetic alopecia.
- Trial name
- NCT07370519
- Testing
- Lactobacillus reuteri, Inactivated Lactobacillus reuteri, 5% Minoxidil
- Where
- China
- Volunteers
- 388 people
- Sponsor
- Shenzhen People's Hospital
Androgenetic Alopecia, AGA
Safety and Efficacy of VDPHL01 in Males With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06972264
- Testing
- VDPHL01
- Where
- 44 sites in United States
- Volunteers
- 480 people
- Sponsor
- Veradermics, Inc.
Androgenetic Alopecia, AGA
Safety and Efficacy of VDPHL01 in Males and Females With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06527365
- Testing
- VDPHL01
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Veradermics, Inc.
Androgenetic Alopecia, AGA
Efficacy and Safety of VDPHL01 in Males With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06724614
- Testing
- VDPHL01
- Where
- 44 sites in United States
- Volunteers
- 480 people
- Sponsor
- Veradermics, Inc.
Androgenetic Alopecia (AGA)
Thulium Laser and Growth Factors for Androgenetic Alopecia
Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and…
- Trial name
- NCT07079657
- Testing
- Thulium laser + growth factor serum + LED, Thulium laser + growth factor serum, Thulium laser
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Androgenetic Alopecia (AGA)
Low Dose Oral Minoxdil in Androgenic Alopecia
In order to successfully treat androgenetic alopecia (AGA), this study compares the efficacy of low-dose oral minoxidil dosages of 0.25 mg and 1 mg.
- Trial name
- NCT07018349
- Testing
- 2.5% Oral minoxidil, 1% Oral Minoxidil
- Where
- Pakistan
- Volunteers
- 76 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Androgenetic Alopecia (AGA)
Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults.
- Trial name
- NCT07012486
- Testing
- Oral DHA + Topical minoxidil 5%, Topical Minoxidil 5%
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Alopecia, Androgenetic, Baldness
A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
This study will evaluate the safety and efficacy of PDFE-2304 compared with Minoxidil 5% in men with androgenic alopecia (AGA).
- Conditions
- Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)
- Trial name
- NEOPILI-2A (NCT07011485)
- Testing
- Minoxidil 5% Topical Solution, PDFE-2304 Topical Solution
- Where
- India
- Volunteers
- 15 people
- Sponsor
- PDFE Pharma Innovations FZCO
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia.
The goal of this study is to learn if mesenchymal stem cell therapy (treatment group) can effectively treat adrogenic alopecia or male-pattern baldness, when compared to normal saline (given to placebo group).
- Trial name
- NCT06764329
- Testing
- Mesenchymal Stem Cells, 0.9 % saline
- Where
- 2 sites in Pakistan
- Volunteers
- 70 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Androgenetic Alopecia (AGA)
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2/3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA).
- Trial name
- NCT06622824
- Testing
- KX-826 0.5% BID, KX-826 1.0% BID
- Where
- China
- Volunteers
- 756 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,